Madrigal Pharmaceuticals: Barclays sees 80% price potential in the biotech!
Reading Time: 3 minutes
Specialization in Advanced Liver Therapies Madrigal Pharmaceuticals (MDGL) is a biopharmaceutical company that is fully dedicated to the development of innovative therapeutics for metabolic-associated steatoh Hepatitis, abbreviated as MASH. At the core of the company's mission is the provision of effective solutions for a disease that has long been characterized by a high unmet medical need. The company's main product, Rezdiffra (Resmetirom), is a once-daily oral THR-β-agonist that directly targets the underlying causes of liver disease. The...
Read this article now with a free account.
Your benefits:
- Every month, you can read 5 articles from the premium section for free.
- Monthly 2 trial issues of the Trader newspaper for free.
- Create a personal watchlist with an overview of news about your stock.
